Aptamer Sciences Inc
Aptamer Sciences Inc, a bio venture company, focuses on the Aptamer technology platform for the development of therapeutic and diagnostic platforms. The company's platforms include aptamer discovery, optimization, and the development of therapeutics and diagnostics for cancer and neurological disorders. It offers AlloMAp and Bi-Functional Aptame (BiFAp) platform programs for therapeutics, as well… Read more
Aptamer Sciences Inc (291650) - Net Assets
Latest net assets as of September 2025: ₩19.78 Billion KRW
Based on the latest financial reports, Aptamer Sciences Inc (291650) has net assets worth ₩19.78 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩25.79 Billion) and total liabilities (₩6.00 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩19.78 Billion |
| % of Total Assets | 76.71% |
| Annual Growth Rate | N/A |
| 5-Year Change | -27.7% |
| 10-Year Change | N/A |
| Growth Volatility | 166.75 |
Aptamer Sciences Inc - Net Assets Trend (2018–2024)
This chart illustrates how Aptamer Sciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Aptamer Sciences Inc (2018–2024)
The table below shows the annual net assets of Aptamer Sciences Inc from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩25.44 Billion | +64.33% |
| 2023-12-31 | ₩15.48 Billion | -47.03% |
| 2022-12-31 | ₩29.22 Billion | -7.11% |
| 2021-12-31 | ₩31.46 Billion | -10.58% |
| 2020-12-31 | ₩35.18 Billion | +406.90% |
| 2019-12-31 | ₩6.94 Billion | +138.01% |
| 2018-12-31 | ₩-18.26 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aptamer Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4216626612000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩14.64 Billion | 57.56% |
| Other Components | ₩78.23 Billion | 307.56% |
| Total Equity | ₩25.44 Billion | 100.00% |
Aptamer Sciences Inc Competitors by Market Cap
The table below lists competitors of Aptamer Sciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Concord Medical Services Holdings
NYSE:CCM
|
$16.41 Million |
|
OY Nofar Energy Ltd
TA:NOFR
|
$16.42 Million |
|
Yjn Co.,Ltd.
TWO:3191
|
$16.42 Million |
|
MMP Industries Limited
NSE:MMP
|
$16.42 Million |
|
Star Media Group Bhd
KLSE:6084
|
$16.40 Million |
|
4C Group AB
ST:4C
|
$16.40 Million |
|
Maxeon Solar Technologies Ltd
NASDAQ:MAXN
|
$16.40 Million |
|
Superdong Fast Ferry Kien Giang JSC
VN:SKG
|
$16.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aptamer Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 15,478,897,060 to 25,436,323,690, a change of 9,957,426,630 (64.3%).
- Net loss of 8,702,303,130 reduced equity.
- Share repurchases of 17,158,500,000 reduced equity.
- New share issuances of 17,158,500,000 increased equity.
- Other factors increased equity by 18,659,729,760.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-8.70 Billion | -34.21% |
| Share Repurchases | ₩17.16 Billion | -67.46% |
| Share Issuances | ₩17.16 Billion | +67.46% |
| Other Changes | ₩18.66 Billion | +73.36% |
| Total Change | ₩- | 64.33% |
Book Value vs Market Value Analysis
This analysis compares Aptamer Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.71x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | ₩-4585.04 | ₩1484.00 | x |
| 2019-12-31 | ₩492.33 | ₩1484.00 | x |
| 2020-12-31 | ₩4155.82 | ₩1484.00 | x |
| 2021-12-31 | ₩1858.06 | ₩1484.00 | x |
| 2022-12-31 | ₩1469.31 | ₩1484.00 | x |
| 2023-12-31 | ₩911.58 | ₩1484.00 | x |
| 2024-12-31 | ₩868.72 | ₩1484.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aptamer Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -34.21%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -803.68%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.26x
- Recent ROE (-34.21%) is below the historical average (-32.15%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -2409.38% | 0.03x | 0.00x | ₩-4.84 Billion |
| 2019 | -55.50% | -945.20% | 0.05x | 1.20x | ₩-4.55 Billion |
| 2020 | -10.92% | -1681.97% | 0.01x | 1.05x | ₩-7.36 Billion |
| 2021 | -12.18% | -1422.73% | 0.01x | 1.06x | ₩-6.98 Billion |
| 2022 | -24.35% | -1986.19% | 0.01x | 1.56x | ₩-10.04 Billion |
| 2023 | -87.87% | -5593.04% | 0.01x | 2.10x | ₩-15.15 Billion |
| 2024 | -34.21% | -803.68% | 0.03x | 1.26x | ₩-11.25 Billion |
Industry Comparison
This section compares Aptamer Sciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aptamer Sciences Inc (291650) | ₩19.78 Billion | 0.00% | 0.30x | $16.41 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |